Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

343
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
343
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Early Evaluation Of Risk Stratification And Clinical Outcomes For Patients With Advanced Breast Cancer Through Combined Monitoring Of Baseline Circulating Tumor Cells And Dna.
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Early Evaluation Of Risk Stratification And Clinical Outcomes For Patients With Advanced Breast Cancer Through Combined Monitoring Of Baseline Circulating Tumor Cells And Dna.

Related Experiment Video

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

8.6K

Early Evaluation of Risk Stratification and Clinical Outcomes for Patients with Advanced Breast Cancer through Combined Monitoring of Baseline Circulating Tumor Cells and DNA.

Qiang Zhang1,2, Zheng Cai3, Lorenzo Gerratana4,5

  • 1Division of Hematology/Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|June 3, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

More Related Videos

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

15.9K
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
08:25

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

11.0K

Related Experiment Videos

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
06:53

Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids

Published on: June 8, 2019

8.6K
Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

15.9K
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
08:25

Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients

Published on: September 9, 2020

11.0K

Baseline circulating tumor cells (CTCs) and ctDNA aid in differentiating advanced breast cancer stages and predicting metastasis. Higher CTC counts and specific ctDNA mutations correlate with poorer prognosis and shorter survival.

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Cancer Biomarkers

Background:

  • Evaluating tumor heterogeneity in advanced breast cancer (BCa) is crucial for metastasis and outcome prediction.
  • Early assessment of tumor characteristics is a clinical challenge in managing advanced BCa.

Purpose of the Study:

  • To investigate the utility of baseline circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) for early differentiation of clinical stages.
  • To assess the role of CTCs and ctDNA in predicting tumor heterogeneity and prognosis in advanced BCa.

Main Methods:

  • 292 BCa patients (254 Stage IV, 38 Stage III) were analyzed for baseline CTCs, CTC-clusters, and plasma ctDNA before treatment.
  • Progression-free survival (PFS) and overall survival were evaluated using proportional hazards regression.

Main Results:

  • Stage IV patients had 9.5 times higher baseline CTCs than Stage III patients.
  • CTC counts <5 correlated with longer PFS; CTC-clusters were exclusive to Stage IV and associated with worse PFS.
  • PIK3CA and ESR1 mutations in ctDNA were linked to organ metastasis and poorer outcomes in Stage IV BCa.

Conclusions:

  • Baseline CTCs, CTC-clusters, and ctDNA mutational profiles can effectively differentiate clinical stages in advanced BCa.
  • These biomarkers enable early prediction of metastasis and patient outcomes, aiding clinical management.